

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

**Full title (164/200 characters): Costs of home-delivered antiretroviral therapy refills for persons living with HIV: evidence from a pilot randomized controlled trial in KwaZulu-Natal, South Africa**

**Short title (70/70 characters): Costs of home-delivered antiretroviral therapy refills in South Africa**

Ashley S. Tseng<sup>1,2\*</sup>, Ruanne V. Barnabas<sup>3,4</sup>, Alastair van Heerden<sup>5,6</sup>, Xolani Ntinga<sup>5</sup>, Maitreyi Sahu<sup>7</sup>

<sup>1</sup> Department of Epidemiology, University of Washington, Seattle, Washington, United States of America

<sup>2</sup> Department of Global Health, University of Washington, Seattle, Washington, United States of America

<sup>3</sup> Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America

<sup>4</sup> Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States of America

<sup>5</sup> Center for Community Based Research, Human Sciences Research Council, Sweetwaters, KwaZulu-Natal, South Africa

<sup>6</sup> South African Medical Research Council/Wits Developmental Pathways for Health Research Unit, Department of Paediatrics, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, Gauteng, South Africa

<sup>7</sup> Department of Health Metrics Sciences, University of Washington, Seattle, Washington, United States of America

\* Corresponding author  
E-mail: [ashleystseng@gmail.com](mailto:ashleystseng@gmail.com) (AST)

Keywords: HIV/AIDS; sub-Saharan Africa; HIV treatment; ART, costing

Word count: 4,119 words

## 40 **Abstract (299/300 words)**

41 Antiretroviral therapy (ART) is needed across the lifetime to maintain viral suppression for  
42 people living with HIV. In South Africa, obstacles to reliable access to ART persist and are  
43 magnified in rural areas, where HIV services are also typically costlier to deliver. A recent pilot  
44 randomized study (the Deliver Health Study) found that home-delivered ART refills, provided at  
45 a low user fee, effectively overcame logistical barriers to access and improved clinical outcomes  
46 in rural South Africa. In the present costing study using the payer perspective, we conducted  
47 retrospective activity-based micro-costing of home-delivered ART within the Deliver Health  
48 Study and when provided at-scale (in a rural setting), and compared to facility-based costs using  
49 provincial expenditure data (covering both rural and urban settings). Within the context of the pilot  
50 Deliver Health Study which had an average of three deliveries per day for three days a week,  
51 home-delivered ART cost (in 2022 USD) \$794 in the first year and \$714 for subsequent years per  
52 client after subtracting client fees, compared with \$167 per client in provincial clinic-based care.  
53 We estimated that home-delivered ART can reasonably be scaled up to 12 home deliveries per day  
54 for five days per week in the rural setting. When delivered at scale, home-delivered ART cost \$267  
55 in the first year and \$183 for subsequent years per client. Average costs of home delivery further  
56 decreased when increasing the duration of refills from three-months to six- and 12-month scripts  
57 (from \$183 to \$177 and \$135 per client, respectively). Personnel costs were the largest cost for  
58 home-delivered refills while ART drug costs were the largest cost of clinic-based refills. When  
59 provided at scale, home-delivered ART in a rural setting not only offers clinical benefits for a hard-  
60 to-reach population but is also comparable in cost to the provincial standard of care.

## 61 **Introduction**

62           Until a cure for HIV is available, reliable access to antiretroviral therapy (ART) is needed  
63 across the lifetime to maintain viral suppression. South Africa has one of the highest burdens of  
64 HIV worldwide with an HIV prevalence of 16% among adults aged 15 and older and a total of 7.8  
65 million people with HIV who require lifetime ART [1]. In the past two decades, the South African  
66 government has invested heavily in their HIV programme, and has made great progress towards  
67 achieving the UNAIDS 95-95-95 treatment targets: as of 2022, 90% of South African adults with  
68 HIV knew their status, 91% of adults who knew their status were on ART, and 94% of people on  
69 ART were virally suppressed [1]. However, the status of HIV control varies considerably across  
70 the nation, with KwaZulu-Natal province continuing to have the highest HIV prevalence in the  
71 country (22%) [1] and rural farming communities reporting higher HIV prevalence than urban  
72 areas (18% vs. 13%) [2]. Access to HIV care is further constrained by slowing government funding  
73 which has not matched the level of demand [3], particularly in rural areas where the cost of  
74 successfully treating HIV is higher due to logistical barriers, supply chain considerations, and  
75 staffing challenges [4]. In light of these rural/urban disparities in HIV outcomes and costs, novel  
76 and low-cost strategies to address gaps in HIV care in rural South Africa are critically needed.

77           A number of strategies have been proposed to improve HIV outcomes and reduce the  
78 burden of care associated with one to three-month ART refill visits for both clients and health  
79 systems [5]. In particular, the World Health Organization now recommends Differentiated Service  
80 Delivery (DSD) for HIV care, which involves tailoring programs to accommodate client needs to  
81 improve HIV treatment outcomes and reduce health system burden [6]. Various client-centered  
82 DSD mechanisms are being proposed to increase viral suppression by overcoming barriers to  
83 accessing HIV care including long wait times at clinics, transportation barriers, and social stigma

84 [7–9]. As a result, alternative ART dispensing mechanisms which reduce clinic burden including  
85 home delivery of medications are being explored and have had demonstrated feasibility and  
86 success in improving client adherence in South Africa [5,10–12].

87 The recent Deliver Health Study found that home-delivered ART and monitoring for a  
88 small user fee increased viral suppression by 21% compared to standard facility-based care among  
89 162 participants in rural KwaZulu-Natal [13]; however, the costs of this program have not  
90 previously been quantified. The objective of the present study was to estimate the cost of home-  
91 delivered ART for adults living with HIV in rural South Africa (1) within the context of the pilot  
92 study and (2) when provided at-scale, compared to standard clinic-based ART resupply. A  
93 secondary objective was to identify cost drivers for each mode of ART delivery. In a sensitivity  
94 analysis, we also estimated cost savings when home-delivered ART used multi-month refill  
95 scripts. This study aims to inform the South African National Department of Health’s (NDoH)  
96 strategy to improve HIV treatment outcomes and reduce health system burden in rural South  
97 Africa.

## 98 **Materials and Methods**

### 99 **Deliver Health Study**

100 The Deliver Health Study (NIH R21MH115770; ClinicalTrials.gov Identifier:  
101 NCT04027153) was a pilot randomized trial of home ART delivery, monitoring, and ART  
102 resupply conducted in three rural and peri-urban communities in uMgungundlovu District,  
103 KwaZulu-Natal from October 2019 to December 2020. The detailed study procedures have been  
104 previously published [14], and are also summarized in the S1 File flow map. Briefly, 162 ART-  
105 eligible [15] adults aged 18 or over with HIV were identified through home and mobile van HIV  
106 testing and counselling and at HIV clinics. Following the enrollment and ART initiation visit,

107 clients were randomized to receive either home delivery of HIV care which was provided for a  
108 small user fee of 30–90 South African Rand (ZAR) (2–7 United States Dollars [USD]), or standard  
109 clinic-based ART follow-up care at a health center of choice within the study catchment area.  
110 Home delivery of HIV care was provided leveraging an optimized delivery algorithm to reduce  
111 travel times and associated costs, described further in the S2 File. For the home delivery arm of  
112 the pilot study, study staff made deliveries three days per week, spent an average of 26 minutes  
113 per home delivery of ART (including transportation time), and made an average of three deliveries  
114 a day. Home delivery was at first implemented by a team of three (nurse, driver, data collector),  
115 but staffing was later reduced to just the nurse due to pandemic social distancing restrictions (S1  
116 File). All Deliver Health Study participants received the TDF/FTC/EFV ART regimen for the  
117 treatment of HIV.

## 118 **Ethics statement and declarations**

119 Ethical approval was obtained from the Human Sciences Research Council Research Ethics  
120 Committee in South Africa (REC 1/21/11/18) and the University of Washington Institutional  
121 Review Board in Seattle, Washington, United States (STUDY00005739). All study participants  
122 provided written informed consent per local ethics committee requirements.

123 Access to Deliver Health Study data was originally granted on March 8, 2022 to AST. AST  
124 had access to information that could potentially identify participants after data collection,  
125 specifically participant locator information.

## 126 **Study population**

### 127 **Deliver Health Study participant demographics**

128 A total of 155 adults living with HIV completed follow-up in the Deliver Health Study, 81  
129 (52%) of whom received home-delivered ART refills and monitoring and 74 (48%) of whom

130 received clinic-based care. The median age of participants was 38 years (interquartile range: 12),  
131 and 72 (47%) were women. Seventy-one (88%) people living with HIV in the home-delivery group  
132 were virally suppressed at study exit compared to 55 (74%) people living with HIV in the clinic-  
133 based care group. The average monthly salary of participants randomized to the home delivery  
134 group, self-reported at baseline, was 1376 ZAR (108 USD) per individual with a standard deviation  
135 of 2247 ZAR (176 USD).

## 136 **Study setting**

137 KwaZulu-Natal was the province in South Africa with the highest estimated HIV  
138 prevalence of 22% among adults aged 15 years and older in 2022 [1], totaling approximately 1.9  
139 million adults [16]. An estimated 52% of the population in KwaZulu-Natal resided in rural areas  
140 [17], and rural districts of KwaZulu-Natal had the highest estimated HIV prevalence in South  
141 Africa of greater than 28% [18]. At the end of 2022, 31% of 15-64 year olds residing in KwaZulu-  
142 Natal were unemployed [19] and the average monthly earnings of employees in the formal non-  
143 agricultural sector was 26,032 ZAR across South Africa [20].

## 144 **Cost estimation**

145 Our primary analysis compared the cost of quarterly home delivery of ART (the pilot  
146 Deliver Health Study intervention) with the Standard of Care (SOC), i.e., clinic-based care with  
147 three-month refill scripts, in KwaZulu-Natal province. Due to limited capacity for costing during  
148 the trial (which was conducted during the COVID-19 pandemic), costs were collected  
149 retrospectively, and the home-delivery and SOC costs relied on different data sources representing  
150 different regions of KwaZulu-Natal, described further below. All costs were estimated from the  
151 payer perspective to inform the South African NDoH's financial planning and strategy. To  
152 quantify resource use [21], we first outlined program activities in a detailed Narrative Summary

153 for the Deliver Health Study (S1 File) which further informed our assumptions regarding  
154 programmatic implementation (S2 File). Our primary outcomes of interest were:

- 155 1) Average annual cost per client: the average annual cost per person living with HIV in the  
156 Deliver Health Study or in KwaZulu-Natal
- 157 2) Average annual cost per client virally suppressed: the average annual cost per person living  
158 with HIV who was virally suppressed in the Deliver Health Study or in KwaZulu-Natal.

159 In our secondary objective, costs for each mode of service delivery were disaggregated by cost  
160 categories (personnel, vehicles and fuel, drugs, etc.) to understand the main cost drivers (detailed  
161 methods in S2 File).

162 Costs were reported in 2022 USD. For costs originally reported in ZAR, we used the  
163 World Bank GDP implicit deflator for South Africa [22] and the average ZAR-to-USD exchange  
164 rate in 2022 [23]. We deflated costs reported in USD using the US annual average Consumer  
165 Price Index [24]. Capital items and other costs with a useful life of more than one year were  
166 discounted 3%. Full details of these adjustments are provided in S2 File.

### 167 **Costing of home delivery of ART and monitoring**

168 For home-delivered refills, we conducted activity-based micro-costing for home-delivered  
169 ART and monitoring in the Deliver Health Study in rural uMgungundlovu District of KwaZulu-  
170 Natal. We excluded costs for research-specific procedures (e.g., data collection, research-related  
171 personnel costs). Personnel salaries were obtained from the Deliver Health Study and South Africa  
172 Department of Public Service and Administration [25]. To estimate personnel time, vehicle costs,  
173 and fuel, we used recorded travel logs for the home delivery trips. We assumed the home-delivery  
174 intervention was delivered by a team of a nurse, a driver, and a community outreach worker. Full  
175 cost assumptions including staff time and vehicle costs are detailed in S2 File.

## 176 **Costing of clinic-based ART refills and care**

177 To estimate costs for clinic-based care, we used provincial government expenditure data  
178 for the full province of KwaZulu-Natal and scaled it to ART-specific care. We obtained actual  
179 HIV/AIDS spending (i.e., the rectified budget) for financial years 2019 and 2020 from the South  
180 African National Treasury [26]. We then estimated the proportion of the HIV program budget used  
181 for ART using a 2020 government HIV/AIDS spending report [27] and applied this proportion to  
182 the total 12-month HIV program budget. Full details for these calculations are in the S2 File. Of  
183 note, clinic expenditure data covered both rural as well as urban areas in KwaZulu-Natal (e.g., the  
184 major cities of Durban and Newcastle), where ART costs may be lower than in rural regions [4].

## 185 **Scenarios**

186 For the home-delivered ART intervention, we modelled two sets of scenarios over a 12-  
187 month time horizon: programmatic and at-scale. Our baseline estimation assumed three-month  
188 (quarterly) refills; in a sensitivity analysis we also estimated the costs of home delivery for six-  
189 and 12-month ART refill scripts starting after the first quarter. Costs of home-delivered ART for  
190 all scenarios were compared to the SOC, i.e., clinic-based care with three-month ART refill scripts.  
191 Full details of the estimation for all scenarios are in S2 File.

## 192 **Programmatic cost estimation**

193 The primary cost was the programmatic scenario for home-delivered ART, which we  
194 estimated to reflect the resource requirements if home-delivered ART were implemented by the  
195 South African NDoH. Accordingly, we substituted staff salaries paid under the Deliver Health  
196 Study with corresponding salaries reported by the South African government [25]. The  
197 programmatic scenario assumed that ART was delivered by a team of two (nurse and driver) who  
198 spent approximately 3.5 hours a day for 3 days a week making home deliveries to support 81



199 clients in the Deliver Health Study, and that the program was also supported by a community  
200 outreach worker and other operational staff (S2 File). In a sensitivity analysis, we also estimated a  
201 second programmatic “as-observed” scenario using staff salaries from within the Deliver Health  
202 Study.

### 203 **At-scale cost estimation**

204         Given the low client volume within the pilot Deliver Health Study, we estimated a scenario  
205 where home delivery of ART was scaled up to accommodate a larger client volume. Granted that  
206 within the Deliver Health Study, the maximum number of deliveries made in a given day was 16  
207 visits and the average time per visit was 26 minutes (including driving), we estimated that the same  
208 team could reasonably make 12 home deliveries a day for five days per week, spending  
209 approximately six hours of their working day making home deliveries to clients and about two  
210 hours to load and unload the delivery vehicle at the central office. This estimation assumed a 40-  
211 hour work week and 214 workdays a year (excluding weekends, holidays, and other leave). In  
212 addition, we assumed an ART initiation visit (which includes HIV counselling) would take three  
213 times as long as an ART refill visit, which was qualitatively informed by time-and-motion  
214 observations conducted during January–February 2023 for an ongoing follow-up trial to the  
215 Deliver Health Study (S2 File).

## 216 **Results**

### 217 **Programmatic scenarios**

218         For the 81 clients receiving home-delivered ART in the Deliver Health Study, cost of home  
219 delivery was substantially higher than provincial estimates for annual per-client facility-based  
220 ART costs. Specifically, we estimated that in the context of the pilot study the average annual cost  
221 per client receiving home-delivered ART refills was \$794 per client and \$907 per client virally

222 suppressed in the first year of intervention and \$714 per client and \$815 per client virally  
223 suppressed for subsequent years, after subtracting paid client fees (Tables 1 and 2). In comparison,  
224 the SOC was estimated to cost an average of \$167 annually per client and \$254 per client virally  
225 suppressed. “As-observed” costs for home-delivered ART in the Deliver Health Study were  
226 somewhat higher in the primary programmatic scenario due to differences in assumptions around  
227 staff salaries (\$819 per client and \$935 per client virally suppressed for quarterly refills in the first  
228 year of intervention). Multi-month scripting scenarios (with six- and 12-monthly refills) further  
229 reduced the cost of home-delivered ART, as shown in Table 2.

230  
231**Table 1. Average annual cost per client and average annual cost per virally suppressed client by refill method within the context of the Deliver Health Study, under the programmatic scenario with 3-month ART refill scripts.**

Cost category	Average annual cost per client						Average annual cost per client virally suppressed					
	Home delivery <sup>a</sup>				Clinic <sup>c,d</sup> N=1,925,698		Home delivery <sup>e</sup>				Clinic <sup>c,d</sup> N=1,270,961	
	First year <sup>b</sup> N=81		Subsequent years N=81				First year <sup>b</sup> N=71		Subsequent years N=71			
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD
	Cost (% of total cost)											
ART drugs	1,150 (9)	70 (9)	1150 (10)	70 (10)	1150 (42)	70 (42)	1,312 (9)	80 (9)	1,312 (10)	80 (10)	1,743 (42)	106 (42)
Buildings and administrative overhead	2,189 (17)	134 (17)	2,091 (18)	128 (18)	58 (2)	4 (2)	2,497 (17)	152 (17)	2,386 (18)	146 (18)	88 (2)	5 (2)
Communication	1,269 (10)	78 (10)	1,269 (11)	78 (11)	6 (0.22)	0.36 (0.22)	1,448 (10)	88 (10)	1,448 (11)	88 (11)	9 (0.22)	0.55 (0.22)
Equipment	1,200 (9)	73 (9)	150 (1)	9 (1)	2 (0.06)	0.11 (0.06)	1,369 (9)	84 (9)	172 (1)	10 (1)	3 (0.06)	0.16 (0.06)
Hiring and training	657 (5)	40 (5)	657 (6)	40 (6)	2 (0.09)	0.15 (0.09)	749 (5)	46 (5)	749 (6)	46 (6)	4 (0.09)	0.22 (0.09)
Materials and supplies	753 (6)	46 (6)	590 (5)	36 (5)	561 (20)	34 (20)	859 (6)	52 (6)	674 (5)	41 (5)	850 (20)	52 (20)
Personnel wages and benefits	4,354 (33)	266 (33)	4,354 (37)	266 (37)	960 (35)	59 (35)	4,968 (33)	303 (33)	4,968 (37)	303 (37)	1454 (35)	89 (35)
Vehicles and fuel	1,491 (11)	91 (11)	1,489 (13)	91 (13)	0.26 (0.01)	0.02 (0.01)	1,701 (11)	104 (11)	1,699 (13)	104 (13)	0.40 (0.01)	0.02 (0.01)
<b>Total<sup>f</sup></b>	13,006	794	11,694	714	2,740	167	14,846	907	13,349	815	4,151	254

232

Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations Programme on HIV/AIDS.

233

<sup>a</sup>There were 81 people living with HIV on ART in the home-delivered ART refills group of the Deliver Health Study.

234

<sup>b</sup>Includes startup costs.

235

<sup>c</sup>The standard-of-care in South Africa is 3-month ART refills at clinics.

236

<sup>d</sup>The total number of adults (aged 15 years and older) living with HIV in KwaZulu-Natal in September 2022 was 1,925,698 people. Source: [UNAIDS HIV sub-national estimates viewer](#).

237

<sup>e</sup>There were 71 people living with HIV on ART who were virally suppressed at study exit in the home-delivered ART refills group of the Deliver Health Study.

238

239

<sup>f</sup>The average fee for home delivery service, about 4 USD, paid by clients in the home delivery intervention of the Deliver Health Study was subtracted from the programmatic costs of implementing home delivery.

240

241

242  
243  
244

**Table 2. Estimated cost implications of multi-month home-delivered and standard clinic-based ART refills and monitoring as-observed by the South African National Department of Health with South African government salaries, under the programmatic scenario with 3-, 6-, and 12-month ART refill scripts.**

Scenario	Average annual cost per client						Average annual cost per client virally suppressed					
	Home delivery				Clinic <sup>b</sup> N=1,925,698		Home delivery				Clinic <sup>b</sup> N=1,270,961	
	First year <sup>a</sup> N=81		Subsequent years N=81				First year <sup>a</sup> N=71		Subsequent years N=71			
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD
Programmatic costs with 3-month refills	13,006	794	11,694	714	2,740	167	14,846	907	13,349	815	4,151	254
Programmatic costs with 6-month refills	10,014	612	9,337	570			11,424	698	10,652	651		
Programmatic costs with 12-month refills	8,261	504	7,521	459			9,424	576	8,581	524		

245  
246  
247  
248  
249  
250

Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations Programme on HIV/AIDS.

<sup>a</sup>Includes startup costs.

<sup>b</sup>The standard-of-care in South Africa is 3-month ART refills at clinics.

251 For home-delivered ART, the largest cost categories were personnel costs (33%), buildings  
252 and overhead (17%), and vehicles and fuel (11%) for the first year of implementation (Fig 1A).  
253 These proportions remained relatively stable for subsequent years (Fig 1B). For the SOC, the  
254 largest costs were ART drugs (42%), personnel costs (35%), and materials and supplies (20%) for  
255 each year of implementation (Fig 1A). Total annual costs by cost category are reported in the S3  
256 File.

257

258 **Figure 1. Average annual cost per client (2022 USD) for home-delivered 3-month ART**  
259 **refills vs. clinic-based 3-month ART refills (standard-of-care) by cost category in the**  
260 **programmatic NDoH-implemented scenario.** The NDoH scenario assumes fixed costs as  
261 implemented in the Deliver Health Study and public sector clinical staff salaries instead of study  
262 salaries.

263 (A) Home-delivered 3-month ART refills (first year costs) vs. standard-of-care. (B) Home-  
264 delivered 3-month ART refills (subsequent year costs) vs. standard-of-care.

265

## 266 **At-scale scenarios**

267 We estimated that if the home delivery team was working full-time (using the parameters  
268 described in the methods), the team could feasibly make 12 home delivery stops per working day  
269 and accommodate a client volume of 367 newly diagnosed people with HIV in the first year and  
270 up to 642 clients in subsequent years. We estimated that this at-scale programmatic cost of home  
271 delivery would be \$267 annually per client for home-delivered ART refills and monitoring in the  
272 first year and \$183 in subsequent years (Table 3), in comparison to \$167 for clinic-based refills.  
273 The average annual cost per client virally suppressed receiving home-delivered ART refills would

274 be \$303 in the first year and \$208 in subsequent years (Table 3) vs. \$254 for clients receiving  
275 clinic-based care.

276  
277

**Table 3. Estimated cost implications of multi-month home-delivered and standard clinic-based ART refills and monitoring provided at-scale by the South African National Department of Health with South African government salaries, with 3-, 6-, and 12-month ART refill scripts.**

Scenario	Average annual cost per client						Average annual cost per client virally suppressed					
	Home delivery				Clinic N=1,925,698		Home delivery				Clinic N=1,270,961	
	First year <sup>b</sup> N=367		Subsequent years N=642				First year <sup>b</sup> N=323		Subsequent years N=565			
	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD	2022 ZAR	2022 USD
At-scale programmatic costs with 3-month refills <sup>a</sup>	4,367	267	2,996	183	2,740	167	4,963	303	3,405	208	4,151	254
At-scale programmatic costs with 6-month refills	3,681	225	2,900	177			4,183	255	3,296	201		
At-scale programmatic costs with 12-month refills	3,921	239	2,214	135			4,455	272	2,516	154		

278  
279  
280  
281

Abbreviations: ART = antiretroviral therapy, ZAR = South African Rand, USD = United States Dollars, HIV = Human Immunodeficiency Virus, UNAIDS = Joint United Nations Programme on HIV/AIDS.

<sup>a</sup>The standard-of-care in South Africa is 3-month ART refills.

<sup>b</sup>Includes startup costs.

282 Multi-month scripting further reduced the cost of home-delivered ART so that it was  
283 comparable or even lower in cost than SOC. With six-month ART refill scripts, the annual cost  
284 per client would be \$225 for home-delivered refills in the first year and \$177 for subsequent years,  
285 (compared to \$167 for the SOC), and the average cost per client virally suppressed would be \$255  
286 in the first year and \$201 in subsequent years (vs. \$254 for the SOC). At-scale 12-month ART  
287 refills would be cost-saving after the first year: the annual cost per client would be \$135 in  
288 subsequent years (compared to \$167 for the SOC) (Table 3).

289 For three-month at-scale home delivered ART, the largest first-year costs were ART drugs  
290 (26%), personnel costs (22%), materials and supplies (17%), and buildings and overheads (12%)  
291 (Fig 2A). The rankings of cost categories remained the same for subsequent years (Fig 2B).  
292 Average client costs per cost category for the six-month refill programmatic and at-scale scenarios  
293 are reported in the S3 File, along with additional cost driver figures.

294

295 **Figure 2. At-scale average annual cost per client (2022 USD) for home-delivered 3-month**  
296 **ART refills vs. clinic-based 3-month ART refills (standard-of-care) by cost category in the**  
297 **programmatic NDoH-implemented scenario.** The NDoH scenario assumes fixed costs as  
298 implemented in the Deliver Health Study and public sector clinical staff salaries instead of study  
299 salaries.

300 (A) Home-delivered ART intervention (first year costs) vs. clinic-based ART refills. (B) Home-  
301 delivered ART intervention (subsequent year costs) vs. clinic-based ART refills.

302

## 303 Discussion



304 In this costing study of home-delivered ART refills in a high-prevalence rural setting in  
305 South Africa, we estimate that when delivered at scale, home delivery costs in a rural setting are  
306 comparable to the SOC of clinic-based refills administered across both rural and urban settings.  
307 Specifically, assuming a reasonable client volume of 12 home deliveries per day, we estimate that  
308 the annual per-client cost of home-delivered ART is \$267 in the first year and \$183 in subsequent  
309 years, as compared to the province-level average of \$167 for clinic-based refills; this corresponds  
310 to a per-client incremental cost of \$100 in the first year and \$16 in subsequent years (Table 3).  
311 These incremental costs were predominantly driven by differences in personnel requirements (Fig  
312 1). Importantly, this comparison covers a rural setting for home-delivered ART and a combined  
313 rural/urban setting for the SOC – the difference in setting may contribute to an increase in observed  
314 incremental costs given prior literature from South Africa which suggests that the cost of  
315 delivering ART is on average 7% more costly in rural areas than in urban areas [4]. Multi-month  
316 scripting (six- and 12-months) even further reduced costs of home delivery compared with  
317 standard clinic-based refills, and were either comparable (six-months) or cost-saving (12-months)  
318 when provided at-scale after the first year (Table 3). The published Deliver Health Study results  
319 demonstrated clinical effectiveness of home-delivered ART [14], and the present costing study  
320 suggests that home-delivered ART can be feasibly scaled up in a high prevalence rural setting in  
321 South Africa at modest incremental cost.

322 Our estimates somewhat differ from other costing studies for DSD and ART delivery in  
323 South Africa. Importantly, our estimates for the SOC using KwaZulu-Natal’s provincial budget  
324 data (\$167 per client annually) are substantially lower than the estimates from the South African  
325 HIV investment case, which estimated that the average cost (in 2022 USD) for providing ART per  
326 client annually across South Africa was \$290 [28]. Using a lower comparator means that our

327 estimates of the incremental cost of home-delivered care are higher than would be if we compared  
328 to the South African HIV investment case. Our estimated at-scale annual per-client costs of ART  
329 with quarterly refills were higher than those observed in the DO ART Study, a study of  
330 community-based ART conducted in the same region of rural South Africa (\$183 in this study,  
331 compared with \$287 in the DO ART Study for subsequent years after adjusting for inflation as  
332 shown in S2 File) [29]. While it is expected that home delivery costs might be higher than  
333 community-based delivery of ART due to increased personnel and fuel costs, an approach like  
334 home delivery would remove the physical access barrier for the client, which could result in better  
335 retention in care and ART adherence. Finally, in line with other studies on multi-month scripting  
336 from Southern Africa which have also found comparable clinical outcomes [30–33], we found that  
337 that increasing the duration of ART scripts to six- and 12-months further reduced costs due to the  
338 fewer follow-up visits.

339         Interestingly, the largest cost category for home-delivered ART was personnel wages and  
340 benefits (33% in the baseline scenario) and not vehicle and fuel costs (11%). Personnel was the  
341 largest cost for a number of reasons. First, within the Deliver Health Study, staff coordinated and  
342 made individual home deliveries based on client delivery preferences. In addition, the protocol  
343 required that clients were physically present at the time of delivery (vs. dropping off refills at their  
344 front door). Thus, planning of delivery trips and routes driven were not always optimized. With a  
345 greater volume of clients, optimized delivery algorithms adapted from routing science-guided  
346 delivery in the private sector [34–36] could be useful in managing client delivery preferences and  
347 delivery personnel time, and may ultimately lower programmatic costs. This point is evidenced by  
348 our findings in the at-scale scenarios, in which ART drugs contributed the largest costs to the  
349 home-delivery intervention in both three- and six-month refill scenarios. Second, we assumed that

350 programmatic implementation of home-delivered ART included a full-time professional nurse at  
351 grade 2 and a driver. These programmatic nurse salaries were in fact higher than the nurse staff  
352 salaries from the Deliver Health Study, which is generally not consistent with the literature [29,37].  
353 Alternative team configurations with task shifting to lower cadre health workers (e.g., lower grade  
354 nurses or community health workers) could be tested in future work to determine effectiveness  
355 and efficiency. Finally, vehicles did not contribute a substantial portion of total estimated costs  
356 due to low diesel and vehicle costs relative to personnel costs.

357 In the Deliver Health Study, clients paid a one-time fee, tiered based on individuals'  
358 income (US \$2, \$4, or \$6), for a six-month ART home delivery service (which was extended due  
359 to COVID-19). User fees in general were well-accepted: in the Deliver Health Study, 98% of  
360 clients paid the full user fee for the home-delivery ART service and 100% reported willingness to  
361 continue to pay a fee for the service due to its perceived convenience and flexibility [9]. Notably,  
362 these client fees for the home delivery service did not substantially offset delivery costs (personnel,  
363 vehicle, and fuel) in either the as-observed or at-scale scenarios. Moreover, the fee in the Deliver  
364 Health Study covered home ART delivery service for six months, thus an annual service fee per  
365 client would likely be higher (e.g., double that of the six-month service) in implementation.  
366 However, the user fees still contributed to a modest reduction in programmatic costs and may  
367 additionally have contributed to program effectiveness [38,39].

368 Our study had a number of limitations. First, as discussed above, our costing of home-  
369 delivered ART covered a rural setting while the SOC covered a rural and urban setting, likely  
370 leading to an overestimate of incremental costs [40]. In a related point, we did not obtain all costing  
371 inputs from a single source; however, we relied on either peer-reviewed studies or published data  
372 from the South African government. Third, our study included a low client volume from pilot

373 randomized controlled trial leading to higher costs per person. To account for the small sample  
374 size, we modelled at-scale scenarios to accommodate a higher client volume; these findings were  
375 more in line with estimates from the literature. Fourth, we estimated costs for TDF/FTC/EFV (the  
376 regimen prescribed for Deliver Health Study participants); however, as of 2023, South Africa  
377 recommends ART regimens containing DTG for greater adherence and viral suppression [15,41]  
378 [42,43] – future costing studies should note this change in clinical guidelines. Fifth, while our  
379 study was conducted from the payer perspective to reflect the stakeholder of interest, a societal  
380 perspective could better capture benefits to clients (e.g., transportation costs, lost wages due to  
381 time spent on clinic visits, childcare [9]). Sixth, this study uses the SOC as the comparison, but  
382 does not compare to costs of other DSD models for HIV, such as the use of community package  
383 lockers (smart lockers) being tested in an ongoing trial throughout rural KwaZulu-Natal [44].  
384 Finally, while the present study does not incorporate health outcomes, the estimates generated in  
385 this study can be leveraged for future cost-effectiveness analysis.

386 National scale-up of DSD models for HIV treatment, tailored to specific patient  
387 populations and geographies, are needed in South Africa. A number of alternative ART dispensing  
388 mechanisms have demonstrated improved medication adherence and retention compared to clinic  
389 care, including home delivery service, community package lockers, and automated pharmacy  
390 dispensing units [45]. These methods, particularly when clients can flexibly choose the most  
391 convenient option, can strengthen individuals' commitment to care [46,47]. Additionally,  
392 community-based ART resupply can increase coverage in rural areas [48] and reduce clinic  
393 congestion [49]. At scale, home-delivered ART could be optimized using a centralized warehouse  
394 to fulfill and dispatch delivery trucks that synchronize deliveries to neighboring locations, similar  
395 to what is used in the private sector by Amazon [50]. These warehouses could even be used for

396 other chronic medications as part of the Centralised Chronic Medicine Dispensing and Distribution  
397 [51], freeing up clinics and pharmacies to focus on clients with health care needs other than refills.  
398 Drone delivery, which has successfully been tested in other African countries including Uganda  
399 (for ART) and Malawi (for transportation of lab samples), offers a promising cost-effective  
400 solution for rural areas [52,53]. In fact, Amazon has recently begun implementing home delivery  
401 of medications via drones in the US [54]. These innovative methods hold promise for addressing  
402 the hard-to-reach and high prevalence populations in rural South Africa, where interventions  
403 increasing early adoption of and adherence to ART can be highly cost-effective (increases cost-  
404 effectiveness relative to the base-case by 23% in a rural areas of South Africa, compared to 1.1%  
405 in urban areas) [4]. Future research should explore the costs and outcomes of various innovative  
406 approaches compared to traditional clinic-based care.

## 407 **Conclusion**

408 Our costing study is a novel evaluation to quantify the costs associated with  
409 implementing home-delivered ART and monitoring in rural South Africa. Implementing home-  
410 delivered ART and monitoring costs more on average annually per client and per client virally  
411 suppressed compared to standard three-month clinic-based ART refills in KwaZulu-Natal, but  
412 incremental costs were reduced when home delivery was scaled to a larger client volume and  
413 potentially even cost-saving when using six- and 12-month refill scripts. The findings of this  
414 study could help inform the South African NDoH's strategy to meet the 95-95-95 targets by  
415 focusing on the scale-up of novel DSD methods, such as home-delivered ART, to promote long-  
416 term retention in HIV care while reducing patient load at public health clinics.

## 417 **Acknowledgements**

418           We would like to thank the Deliver Health Study Team and the individuals who  
419 participated in the study.

## 420 **References**

- 421 1. Human Sciences Research Council. SABSSM VI The Sixth South African National HIV  
422 Prevalence, Incidence, Behaviour and Communication Survey: Summary Sheet. Cape  
423 Town; 2023.
- 424 2. Simbayi L, Zuma K, Zungu N, Moyo S, Marinda E, Jooste S, et al. South African  
425 National HIV Prevalence, Incidence, Behaviour and Communication Survey, 2017. Cape  
426 Town; 2019. Available: <https://hsrc.ac.za/uploads/pageContent/10779/SABSSM V.pdf>
- 427 3. Malakoane B, Heunis JC, Chikobvu P, Kigozi NG, Kruger WH. Public health system  
428 challenges in the Free State, South Africa: a situation appraisal to inform health system  
429 strengthening. *BMC Health Serv Res.* 2020;20: 58. doi:10.1186/s12913-019-4862-y
- 430 4. Mbonigaba J, Oumar SB. The cost-effectiveness of major HIV/AIDS interventions in  
431 rural and urban areas in South Africa. *Int J Econ Bus Res.* 2017;13: 413.  
432 doi:10.1504/IJEER.2017.084387
- 433 5. Grimsrud A, Wilkinson L. Acceleration of differentiated service delivery for HIV  
434 treatment in sub-Saharan Africa during COVID-19. *J Int AIDS Soc.* 2021;24.  
435 doi:10.1002/jia2.25704
- 436 6. World Health Organization. Consolidated guidelines on HIV prevention, testing,  
437 treatment, service delivery and monitoring: recommendations for a public health  
438 approach. Geneva; 2021. Available:  
439 <https://www.who.int/publications/i/item/9789240031593>
- 440 7. Nicol E, Jama NA, Mehlomakulu V, Hlongwa M, Pass D, Basera W, et al. Enhancing  
441 linkage to HIV care in the “Universal Test and Treat” era: Barriers and enablers to HIV  
442 care among adults in a high HIV burdened district in KwaZulu-Natal, South Africa. *BMC*

- 443 Public Health. 2023;23: 1756. doi:10.1186/s12889-023-16576-w
- 444 8. Iwuji C, Chimukuche RS, Zuma T, Plazy M, Larmarange J, Orne-Gliemann J, et al. Test  
445 but not treat: Community members' experiences with barriers and facilitators to universal  
446 antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. Yotebieng M, editor.  
447 PLoS One. 2020;15: e0239513. doi:10.1371/journal.pone.0239513
- 448 9. Ntinga X, Musiello F, Pita T, Mabaso N, Celum C, Szpiro A, et al. People living with  
449 HIV's perspectives of acceptability of fee for home delivery of ART: a qualitative study.  
450 BMC Health Serv Res. 2024;24: 88. doi:10.1186/s12913-023-10533-4
- 451 10. Brey Z, Mash R, Goliath C, Roman D. Home delivery of medication during Coronavirus  
452 disease 2019, Cape Town, South Africa: Short report. African J Prim Heal care Fam Med.  
453 2020;12: e1–e4. doi:10.4102/phcfm.v12i1.2449
- 454 11. Mash RJ, Schouw D, Daviaud E, Besada D, Roman D. Evaluating the implementation of  
455 home delivery of medication by community health workers during the COVID-19  
456 pandemic in Cape Town, South Africa: a convergent mixed methods study. BMC Health  
457 Serv Res. 2022;22: 98. doi:10.1186/s12913-022-07464-x
- 458 12. Huber A, Pascoe S, Nichols B, Long L, Kuchukhidze S, Phiri B, et al. Differentiated  
459 Service Delivery Models for HIV Treatment in Malawi, South Africa, and Zambia: A  
460 Landscape Analysis. Glob Heal Sci Pract. 2021;9: 296–307. doi:10.9745/GHSP-D-20-  
461 00532
- 462 13. Barnabas R V, Szpiro A, Ntinga X, Mugambi ML, Krows ML, Schaafsma TT, et al. Fee  
463 for home delivery and monitoring of ART raises viral suppression in South Africa.  
464 Conference on Retroviruses and Opportunistic Infections (CROI). 2021. Available:  
465 <https://www.croiconference.org/abstract/fee-for-home-delivery-and-monitoring-of-art->



- 466 raises-viral-suppression-in-south-africa/
- 467 14. Barnabas R V, Szpiro AA, Ntinga X, Mugambi ML, van Rooyen H, Bruce A, et al. Fee  
468 for home delivery and monitoring of antiretroviral therapy for HIV infection compared  
469 with standard clinic-based services in South Africa: a randomised controlled trial. *Lancet*  
470 *HIV*. 2022;9: e848–e856. doi:10.1016/S2352-3018(22)00254-5
- 471 15. Republic of South Africa National Department of Health. 2023 ART Clinical Guidelines  
472 for the Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents,  
473 Children, Infants and Neonates. Pretoria; 2023. Available:  
474 [https://www.differentiatedservicedelivery.org/wp-content/uploads/National-ART-Clinical-](https://www.differentiatedservicedelivery.org/wp-content/uploads/National-ART-Clinical-Guideline-2023_06_06-version-3-Web.pdf)  
475 [Guideline-2023\\_06\\_06-version-3-Web.pdf](https://www.differentiatedservicedelivery.org/wp-content/uploads/National-ART-Clinical-Guideline-2023_06_06-version-3-Web.pdf)
- 476 16. UNAIDS. HIV sub-national estimates viewer. In: UNAIDS [Internet]. 2024 [cited 15 Feb  
477 2024]. Available: <https://naomi-spectrum.unaids.org/>
- 478 17. South African Department of Water and Sanitation. WSA: PROVINCIAL [NAT]  
479 DEMOGRAPHY. 2024 [cited 9 Apr 2024]. Available:  
480 [https://ws.dws.gov.za/wsk/DefaultList.aspx?SubjectAreaID=1&DataTopicDetailID=92&](https://ws.dws.gov.za/wsk/DefaultList.aspx?SubjectAreaID=1&DataTopicDetailID=92&DisplayTypeID=1&PerspectiveID=0&LvlID=10&DataTopicID=1)  
481 [DisplayTypeID=1&PerspectiveID=0&LvlID=10&DataTopicID=1](https://ws.dws.gov.za/wsk/DefaultList.aspx?SubjectAreaID=1&DataTopicDetailID=92&DisplayTypeID=1&PerspectiveID=0&LvlID=10&DataTopicID=1)
- 482 18. South Africa Estimates and Modelling Technical Working Group. South Africa District  
483 HIV Estimates. 2023 [cited 9 Mar 2024]. Available: <https://www.hivdata.org.za/>
- 484 19. Statistics South Africa. Statistical Release P0211 Quarterly Labour Force Survey Quarter  
485 4: 2022. Pretoria; 2023. Available:  
486 <https://www.statssa.gov.za/publications/P0211/P02114thQuarter2022.pdf>
- 487 20. Statistics South Africa. Statistical Release P0277 Quarterly employment statistics (QES)  
488 December 2022. Pretoria; 2023. Available:

- 489 <https://www.statssa.gov.za/publications/P0277/P0277December2022.pdf>
- 490 21. Vassall A, Sweeney S, Kahn J, Gomez GB, Bollinger L, Marseille E, et al. Reference  
491 Case for Estimating the Costs of Global Health Services and Interventions. 2017.  
492 Available:  
493 [https://researchonline.lshtm.ac.uk/id/eprint/4653001/1/vassall\\_etal\\_2018\\_reference\\_case\\_](https://researchonline.lshtm.ac.uk/id/eprint/4653001/1/vassall_etal_2018_reference_case_for_estimating_costs_global_health_services.pdf)  
494 [for\\_estimating\\_costs\\_global\\_health\\_services.pdf](https://researchonline.lshtm.ac.uk/id/eprint/4653001/1/vassall_etal_2018_reference_case_for_estimating_costs_global_health_services.pdf)
- 495 22. The World Bank. GDP deflator (base year varies by country) - South Africa. In: The  
496 World Bank [Internet]. 2024 [cited 10 Dec 2023]. Available:  
497 <https://data.worldbank.org/indicator/NY.GDP.DEFL.ZS?locations=ZA>
- 498 23. Exchange Rates UK. US Dollar (USD) to South African Rand (ZAR) exchange rate  
499 history. In: Exchange Rates UK [Internet]. 2024 [cited 10 Dec 2023]. Available:  
500 <https://www.exchangerates.org.uk/USD-ZAR-exchange-rate-history.html>
- 501 24. U.S. Bureau of Labor Statistics. Databases, Tables & Calculators by Subject: Consumer  
502 Price Index for All Urban Consumers (CPI-U). In: U.S. Bureau of Labor Statistics  
503 [Internet]. 2024 [cited 19 Mar 2024]. Available:  
504 <https://data.bls.gov/timeseries/CUUR0000SA0>
- 505 25. South Africa Department of Public Service and Administration. Appendices A to H4 to  
506 COLA 2021: 2019 and 2021 salary scales, with translation keys, for employees on salary  
507 levels 1 to 12 and those employees covered by Occupation Specific Dispensations  
508 (OSDs). In: South Africa Department of Public Service and Administration [Internet].  
509 2021 [cited 8 Feb 2024]. Available:  
510 [https://www.dpsa.gov.za/dpsa2g/documents/rp/2021/Appendices A to H4 to COLA](https://www.dpsa.gov.za/dpsa2g/documents/rp/2021/Appendices%20A%20to%20H4%20to%20COLA%202021.xlsx)  
511 [2021.xlsx](https://www.dpsa.gov.za/dpsa2g/documents/rp/2021/Appendices A to H4 to COLA 2021.xlsx)

- 512 26. South African National Treasury. Budgeted and Actual Provincial Expenditure. In:  
513 Vulekamali [Internet]. 2024 [cited 29 Jan 2024]. Available:  
514 [https://vulekamali.gov.za/datasets/budgeted-and-actual-provincial-expenditure/budgeted-](https://vulekamali.gov.za/datasets/budgeted-and-actual-provincial-expenditure/budgeted-and-actual-provincial-expenditure)  
515 [and-actual-provincial-expenditure](https://vulekamali.gov.za/datasets/budgeted-and-actual-provincial-expenditure/budgeted-and-actual-provincial-expenditure)
- 516 27. Davén J, Khoele A, Manamela L. 2020 HIV/AIDS Component of the HIV, TB, Malaria  
517 and Community Outreach Grant - an analysis of expenditure per output and options for  
518 future reform. Pretoria; 2021. Available: [https://www.gtac.gov.za/pepa/wp-](https://www.gtac.gov.za/pepa/wp-content/uploads/2021/11/HIV-TB-Spending-Review-Report.pdf)  
519 [content/uploads/2021/11/HIV-TB-Spending-Review-Report.pdf](https://www.gtac.gov.za/pepa/wp-content/uploads/2021/11/HIV-TB-Spending-Review-Report.pdf)
- 520 28. Meyer-Rath G, van Rensburg C, Chiu C, Leuner R, Jamieson L, Cohen S. The per-patient  
521 costs of HIV services in South Africa: Systematic review and application in the South  
522 African HIV Investment Case. McCreesh N, editor. PLoS One. 2019;14: e0210497.  
523 doi:10.1371/journal.pone.0210497
- 524 29. Barnabas R V, Szpiro AA, van Rooyen H, Asiimwe S, Pillay D, Ware NC, et al.  
525 Community-based antiretroviral therapy versus standard clinic-based services for HIV in  
526 South Africa and Uganda (DO ART): a randomised trial. Lancet Glob Heal. 2020;8:  
527 e1305–e1315. doi:10.1016/S2214-109X(20)30313-2
- 528 30. Benade M, Nichols BE, Fatti G, Kuchukhidze S, Takarinda K, Mabhena-Ngorima N, et al.  
529 Economic evaluation of a cluster randomized, non-inferiority trial of differentiated service  
530 delivery models of HIV treatment in Zimbabwe. Pai M, editor. PLOS Glob Public Heal.  
531 2023;3: e0000493. doi:10.1371/journal.pgph.0000493
- 532 31. Nichols BE, Cele R, Lekodeba N, Tukei B, Ngorima-Mabhena N, Tiam A, et al.  
533 Economic evaluation of differentiated service delivery models for HIV treatment in  
534 Lesotho: costs to providers and patients. J Int AIDS Soc. 2021;24. doi:10.1002/jia2.25692

- 535 32. Le Tourneau N, Germann A, Thompson RR, Ford N, Schwartz S, Beres L, et al.  
536 Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and  
537 antiretroviral treatment refills: A systematic review and meta-analysis. Newell M-L,  
538 editor. PLOS Med. 2022;19: e1003959. doi:10.1371/journal.pmed.1003959
- 539 33. Lewis L, Sookrajh Y, van der Molen J, Khubone T, Sosibo P, Maraj M, et al. Clinical  
540 outcomes after extended 12-month antiretroviral therapy prescriptions in a  
541 community-based differentiated HIV service delivery programme in South Africa: a  
542 retrospective cohort study. J Int AIDS Soc. 2023;26. doi:10.1002/jia2.26164
- 543 34. Zhang J, Lam WHK, Chen BY. On-time delivery probabilistic models for the vehicle  
544 routing problem with stochastic demands and time windows. Eur J Oper Res. 2016;249:  
545 144–154. doi:10.1016/j.ejor.2015.08.050
- 546 35. Wang J, Zhou Y, Wang Y, Zhang J, Chen CLP, Zheng Z. Multiobjective Vehicle Routing  
547 Problems With Simultaneous Delivery and Pickup and Time Windows: Formulation,  
548 Instances, and Algorithms. IEEE Trans Cybern. 2016;46: 582–594.  
549 doi:10.1109/TCYB.2015.2409837
- 550 36. Chen X, Zhang Z, Fries R. Development and implementation of algorithms for vehicle  
551 routing during a no-notice evacuation. Loxton R, editor. Cogent Math. 2016;3: 1163767.  
552 doi:10.1080/23311835.2016.1163767
- 553 37. Roberts DA, Barnabas R V, Abuna F, Lagat H, Kinuthia J, Pintye J, et al. The role of  
554 costing in the introduction and scale-up of HIV pre-exposure prophylaxis: evidence from  
555 integrating PrEP into routine maternal and child health and family planning clinics in  
556 western Kenya. J Int AIDS Soc. 2019;22. doi:10.1002/jia2.25296
- 557 38. Ashraf N, Berry J, Shapiro JM. Can Higher Prices Stimulate Product Use? Evidence from

- 558 a Field Experiment in Zambia. *Am Econ Rev.* 2010;100: 2383–2413. Available:  
559 <http://www.aeaweb.org/articles.php?doi=10.1257/aer.100.5.2383>
- 560 39. El-Shal A, Cubi-Molla P, Jofre-Bonet M. Are user fees in health care always evil?  
561 Evidence from family planning, maternal, and child health services. *Econ Anal Policy.*  
562 2021;72: 506–529. doi:10.1016/j.eap.2021.08.009
- 563 40. Statistics South Africa. *Statistics South Africa Provincial Profile 2004: KwaZulu-Natal.*  
564 Pretoria; 2006. Available: [https://www.statssa.gov.za/publications/Report-00-91-](https://www.statssa.gov.za/publications/Report-00-91-05/Report-00-91-052004.pdf)  
565 [05/Report-00-91-052004.pdf](https://www.statssa.gov.za/publications/Report-00-91-052004.pdf)
- 566 41. World Health Organization. WHO recommends dolutegravir as preferred HIV treatment  
567 option in all populations. In: World Health Organization [Internet]. 2019 [cited 7 Mar  
568 2024]. Available: [https://www.who.int/news/item/22-07-2019-who-recommends-](https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations)  
569 [dolutegravir-as-preferred-hiv-treatment-option-in-all-populations](https://www.who.int/news/item/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations)
- 570 42. The NAMSAL ANRS 12313 Study Group. Dolutegravir-Based or Low-Dose Efavirenz-  
571 Based Regimen for the Treatment of HIV-1. *N Engl J Med.* 2019;381: 816–826.  
572 doi:10.1056/NEJMoa1904340
- 573 43. Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al.  
574 Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. *N Engl J Med.*  
575 2019;381: 803–815. doi:10.1056/NEJMoa1902824
- 576 44. van Heerden A, Szpiro A, Ntinga X, Celum C, van Rooyen H, Essack Z, et al. A  
577 Sequential Multiple Assignment Randomized Trial of scalable interventions for ART  
578 delivery in South Africa: the SMART ART study. *Trials.* 2023;24: 32.  
579 doi:10.1186/s13063-022-07025-x
- 580 45. Mash R, Christian C, Chigwanda R V. Alternative mechanisms for delivery of medication

- 581 in South Africa: A scoping review. *South African Fam Pract.* 2021;63: e1–e8.  
582 doi:10.4102/safp.v63i1.5274
- 583 46. Wieber F, Thürmer JL, Gollwitzer PM. Promoting the translation of intentions into action  
584 by implementation intentions: behavioral effects and physiological correlates. *Front Hum*  
585 *Neurosci.* 2015;9. doi:10.3389/fnhum.2015.00395
- 586 47. Hagger MS, Luszczynska A, de Wit J, Benyamini Y, Burkert S, Chamberland P-E, et al.  
587 Implementation intention and planning interventions in Health Psychology:  
588 Recommendations from the Synergy Expert Group for research and practice. *Psychol*  
589 *Health.* 2016;31: 814–839. doi:10.1080/08870446.2016.1146719
- 590 48. Luque-Fernandez MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M,  
591 Mantangana N, et al. Effectiveness of Patient Adherence Groups as a Model of Care for  
592 Stable Patients on Antiretroviral Therapy in Khayelitsha, Cape Town, South Africa.  
593 Dowdy DW, editor. *PLoS One.* 2013;8: e56088. doi:10.1371/journal.pone.0056088
- 594 49. van Heerden A, Ntinga X, Lippman SA, Leslie HH, Steward WT. Understanding the  
595 factors that impact effective uptake and maintenance of HIV care programs in South  
596 African primary health care clinics. *Arch Public Heal.* 2022;80: 221. doi:10.1186/s13690-  
597 022-00975-3
- 598 50. Lenharo M. The science behind grouping package deliveries. In: Amazon Science  
599 [Internet]. 2022 [cited 14 Mar 2024]. Available: [https://www.amazon.science/latest-](https://www.amazon.science/latest-news/the-science-behind-grouping-amazon-package-deliveries)  
600 [news/the-science-behind-grouping-amazon-package-deliveries](https://www.amazon.science/latest-news/the-science-behind-grouping-amazon-package-deliveries)
- 601 51. South Africa National Department of Health. dablapmeds. In: South Africa National  
602 Department of Health [Internet]. 2024 [cited 7 Mar 2024]. Available:  
603 <https://www.health.gov.za/ccmdd/>

- 604 52. UNICEF Malawi. The Drones Factsheet. 2018. Available:  
605 <https://www.unicef.org/malawi/reports/drones-factsheet>
- 606 53. Goad K. How drones are being used to deliver lifesaving HIV drugs to remote areas of the  
607 world. Johnson & Johnson. 21 Jul 2021. Available:  
608 <https://www.jnj.com/innovation/medical-drones-deliver-hiv-medicine>
- 609 54. Amazon Staff. Get medications faster with drone delivery from Amazon Pharmacy.  
610 Amazon News. Oct 2023. Available: [https://www.aboutamazon.com/news/retail/amazon-](https://www.aboutamazon.com/news/retail/amazon-pharmacy-amazon-air-prescription-drone-delivery)  
611 [pharmacy-amazon-air-prescription-drone-delivery](https://www.aboutamazon.com/news/retail/amazon-pharmacy-amazon-air-prescription-drone-delivery)  
612  
613

614 **Supporting information captions**

615 **S1 File. Narrative summary of the Deliver Health Study.**

616 **S2 File. Additional methods.**

617 **S3 File. Additional results.**






Fig 1A




Fig 1B




Fig 2A




Fig 2B